Seeking Alpha alternative · transparent math
Seeking Alpha is a marketplace for analyst takes. Some are excellent; many are wrong; the lock-in is the paywall and the author you follow. Framler replaces the author with a Bayesian factor engine: thirteen academic factors, a confluence pattern library, conformal prediction intervals, full methodology on a public page. Different product, same shelf.
One sells opinion behind a paywall. The other ships a math engine and a published track record.
On Seeking Alpha you pick an author and trust them. On Framler you read the methodology and audit the math. Both are valid mental models — but only one survives an author leaving the platform, and only one gives you the same answer no matter who you ask. We built the second one.
Quality is Novy-Marx 2013. Value is Fama-French. Momentum is Jegadeesh-Titman 1993. NLP tone is Loughran-McDonald 2011 + Li 2008. PEAD is Bernard-Thomas 1989. Insider flow is Seyhun 1986. Phase 3 base rate is Hay et al. 2014. The bibliography lives on /methodology. You don't need an author to summarise — you read the source.
A Seeking Alpha "Strong Buy" article is one author's thesis. A Framler score arrives with a Mondrian conformal interval that says "78 ± 14 at 90% coverage on this regime/sector cohort." The interval is the model telling you when to ignore itself, which a single article never does.
Pharma authors on Seeking Alpha can be excellent — but you're getting one person's read on enrollment, endpoints, and mechanism. Framler runs the Bayesian model on every Healthcare-sector ticker continuously: Hay 2014 base rate updated with log-likelihood-ratios from real ClinicalTrials.gov enrollment velocity, endpoint amendments, and PubMed mechanism evidence. Same input data, structurally consistent output.
The Seeking Alpha Quant Rating (A–F) blends five factors with publicly cited methodology and a Bayesian regime overlay. Framler is a 0–100 composite blending thirteen factors with public weighting and academic citations. Plus we ship a confidence interval per score, a confluence pattern library with academic citations, and Phase 3 failure prediction for biotech. Different category — closer to a hedge-fund factor model than to a paid screener.
Seeking Alpha Premium is $239/year, Pro is $2,400/year. Framler has no equivalent paywall — Quant Ratings on SA require Premium, but the Framler score, every confluence pattern, conformal prediction intervals, and Phase 3 biotech failure model are visible on every ticker page without a sign-up wall. The two products serve different jobs: Seeking Alpha for analyst commentary, Framler for the calibrated quant read.
For factor scoring and pattern detection, yes — that's what the engine does, and it does it consistently across 1000+ tickers. For long-form qualitative analysis on a single name, no — Seeking Alpha's author marketplace is unmatched there. The two are complements, not substitutes. Use Framler to find candidates; read articles for narrative; let your own judgment combine them.
Every signal we generate is logged to signal_history with a timestamp before any forward return is known. After each horizon window we backfill the realised return — zero hindsight bias, no curve-fitting. The out-of-sample window opened 16 May 2026; 1d + 7d horizon accuracy is now live on /track-record. 30d (~26 Jun) and 90d (~15 Sep) horizons roll in as their windows mature.
Type any of 1000+ tickers — you get the full Framler multi-factor breakdown, the regime context, every confluence pattern firing, and the conformal prediction interval. The same answer for everyone, derived from the same paper-cited factors.